However, their overexpression is mainly found ingastrointestinal cancer, opposite to lung and breast cancers for FGFR1.The efficiency of R4Fu-Q65R-MMAE in vivo suggests the legitimacy oftesting peptibodyC19-PEG4MMAE in animal models to furthercharacterize its potential for anticancer treatment. This evidence concerns the gene FGFR1 and breast carcinoma.